Download - GIT Cholestatic AI HBD 17
![Page 1: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/1.jpg)
Autoimmune & Cholestatic liver diseases:
Dr. Mohammad Shaikhani.MBChB- CABM- FRCP-EBGH.
2017 update
![Page 2: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/2.jpg)
![Page 3: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/3.jpg)
![Page 4: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/4.jpg)
Intrahepatic Cholestasis:•Jaundice.
•High TSB, More direct.•Liver enzymes elevated.
•Elevated SAP.•No extrahepatic obstruction on imaging.
![Page 5: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/5.jpg)
AI Cholestatic liver disease:• PBC.• PSC.• IG4-related pancreatobiliary disease.• AIH.
![Page 6: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/6.jpg)
AI Cholestatic liver disease: DD• Medical cholestasis:• Cholestatic phase of viral hepatitis.• Drug-induced cholestasis. • Herbals-induced cholestasis.• Intrahepatic cholestasis of pregnancy.• Alcoholic hepatitis.• Metabolic causes as Wilson disease. • Surgical cholestasis:• Intrahepatic or extrahepatic biliary obstruction on imaging.
![Page 7: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/7.jpg)
Primary Biliary Cirrhosis (Now cholangitis): • PBC occurs primarily in women between 40 - 60 years. • The most common symptom is persistent fatigue. • An antimitochondrial antibody titer of ≥1:40 is the serologic
hallmark for the diagnosis
![Page 8: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/8.jpg)
Primary Biliary cholangitis: EPIDEMIOLOGY
• A chronic progressive cholestatic liver disease of unknown cause. • It is an autoimmune disorder occurs predominantly in women
(80- 90%) between 40- 60 years. • The prevalence has been increasing, most likely because of
earlier diagnosis & increased survival.
![Page 9: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/9.jpg)
Primary Biliary cholangitis: Features
• The most common symptom is persistent fatigue, occurs in 80%. • Either localized or general pruritus frequently develops. • The pruritus often begins in the perineal area or on the palmar /
plantar surfaces typically worse at night or in a warm environment.
• Jaundice / abdominal pain may also develop. • Many patients may be asymptomatic at presentation.
![Page 10: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/10.jpg)
Primary Biliary cholangitis:Physical exam
• Include skin thickening, hyperpigmentation from repeated excoriations, xanthomas, xanthelasma,hepatomegaly.
• Patients with advanced disease may have clinical manifestations of portal hypertension.
• Other autoimmune diseases are frequently present.• Metabolic bone disease, hypercholesterolemia, fat-soluble vitamin
deficiencies are common.
![Page 11: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/11.jpg)
Primary Biliary cholangitis: Diagnosis
• The diagnostic triad includes cholestatic liver profile, positive antimitochondrial antibody titers&compatible histologic findings on liver biopsy.
• SAP & γ-GT are usually elevated *10 or more above normal. • TSB increases as the disease progresses & a helpful prognostic
marker. • An antimitochondrial antibody titer of ≥1:40 is the serologic
hallmark occurs in 90-95% . • The titer does not appear to correlate with the severity or
progression of the clinical disease. • The diagnosis is confirmed by liver biopsy, characteristically
shows nonsuppurative cholangitis plus findings ranging from bile duct lesions to cirrhosis.
![Page 12: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/12.jpg)
Primary Biliary cholangitis: Treatment
• Ursodeoxycholic acid improves the biochemical profile, reduces pruritus, decreases progression to cirrhosis&delays the need for liver transplantation.
• Therapy is usually continued indefinitely. • Liver transplantation is considered for patients with intractable
pruritus or complications from cirrhosis.• Long-term outcomes tend be better than outcomes achieved for
other indications for transplantation.
![Page 13: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/13.jpg)
PSC: Epidemiology • A chronic cholestatic liver disease of unknown cause
characterized by progressive bile duct destruction& may lead to secondary biliary cirrhosis.
• The disease develops more often in men than in women (3:1), generally occurs in patients 20-30 years.
• Up to 80% have an IBD (most often ulcerative colitis), but < 5% with UC develop PSC.
![Page 14: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/14.jpg)
PSC: Features • The most common presenting symptoms are pruritus, jaundice,
abdominal pain, fatigue, although almost 50% of patients are asymptomatic at initial diagnosis.
• Patients with more advanced disease may present with cirrhosis & related complications.
• Other associated disorders include bacterial cholangitis, pigmented bile stones, steatorrhea, malabsorption, metabolic bone disease.
![Page 15: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/15.jpg)
PSC: Diagnosis • Lab findings include a cholestatic liver profile, with SAP *3-5>
normal& mild hyperbilirubinemia. • The diagnosis is confirmed by ERCP or MRCP that shows
findings of multifocal strictures / dilatation of the intra& extrahepatic bile ducts, resembling beads on a string.
• Liver biopsy is usually done for staging rather than for diagnosis may show histologic findings ranging from portal hepatitis to biliary cirrhosis.
• The classic histologic lesion, termed periductal (“onionskin”) fibrosis, is seen in only 10% of biopsy specimens.
![Page 16: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/16.jpg)
PSC: Cholangiography
MRCP ERCP
![Page 17: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/17.jpg)
Primary Sclerosing Cholangitis: DD • Bile duct surgical injury.• Infectious cholangitis (including AIDS cholangiopathy) • Malignancy.
![Page 18: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/18.jpg)
PSC: Complications • Cholangiocarcinoma CC ( 10-30%). • Detecting CC at an early stage is difficult.• Tumor markers CA 19-9+/- CEA• Cytologic sampling through ERCP or cholangioscopy.• Patients with advanced disease& cirrhosis are at risk for HCC.• Patients with both PSC& UC have an increased risk of CRC&
aggressive surveillance needed.
![Page 19: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/19.jpg)
PSC: Management • Includes assessment & management of dominant strictures• Treatment of superimposed bacterial cholangitis• Symptomatic therapy. • Only liver transplantation improves overall survival & quality of
life. • Up to date no TRT has provided the long-term benefits of
transplantation. • Median survival from the time of diagnosis is 12 years.
![Page 20: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/20.jpg)
![Page 21: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/21.jpg)
![Page 22: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/22.jpg)
![Page 23: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/23.jpg)
![Page 24: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/24.jpg)
![Page 25: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/25.jpg)
![Page 26: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/26.jpg)
![Page 27: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/27.jpg)
![Page 28: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/28.jpg)
![Page 29: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/29.jpg)
BO5:1•1.The main point in differentiating intrahepatic from
extra-hepatic cholestasis is:•A. TSB.•B. SAP.
•C. Liver enzymes.•D. Obstruction on imaging.
•E. Fever.
![Page 30: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/30.jpg)
BO5:2•2 .Autoimmune cholestatic liver diseases include:
•A. Wilson disease.•B. Alcholoic liver disease.
•C. Viral-induced cholestasis.•D. Primary biliary & primary sclerosing cholangitis.
•E. Drug-induced cholangitis.
![Page 31: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/31.jpg)
BO5:3•3 .Characteristic features of BPC include all except:
•A. More in women.•B. More in middle ages.
•C. High anti-mitochondrial antibodies.•D. Associated with IBD.
•E. Response to Ursodeoxycholic acid.
![Page 32: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/32.jpg)
BO5:4•4 .PSC is characterized by all except:
•A. More in women.•B. More in youngs.
•C. Predisposes to cholangiocarcinoma.•D. Associated with IBD.
•E. No response to Ursodeoxycholic acid.
![Page 33: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/33.jpg)
BO5:5•5 .PBC differs from PSC by:•A. Occurring in young males.
•B. Causing intrahepatic cholestasis.•C. Responding to ursodeoxycholic acid.
•D. Causing pruritus.•E. High serum alkaline phosphatase.
![Page 34: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/34.jpg)
BO5:6•6 .Good prognostic marker of PBC is:
•A. AMA titer.•B. TSB.•C. SAP.
•D. Liver enzymes level.•E. Pruritus.
![Page 35: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/35.jpg)
BO5:7•7 .Pregnancy-related liver diseases include all
except:•A. Hypermesis.
•B. Toxemia.•C. Intrahepatic cholestasis.
•D. Acute fatty liver.•E. PBC.
![Page 36: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/36.jpg)
BO5:8•8 .The following lab tests are abnormal in normal
pregnancy except:•A. WBC.
•B. SAP.•C. Albumin.
•D. Liver enzymes.•E. Alpha feto protein.
![Page 37: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/37.jpg)
BO5:9•9 .The most common pregnancy-related liver
disease is:•A. Acute fatty liver of pregnancy.
•B. Hyperemesis gravidarum.•C. Toxemia of pregnancy.
•D. Intrahepatic cholestsis of pregnancy.•E. HELP syndrome.
![Page 38: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/38.jpg)
BO5:10•10 .The most seious pregnancy-related liver disease
is:•A. Acute fatty liver of pregnancy.
•B. Hyperemesis gravidarum.•C. Toxemia of pregnancy.
•D. Intrahepatic cholestsis of pregnancy.•E. HELP syndrome.
![Page 39: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/39.jpg)
BO5:11•11 .The most benign pregnancy-related liver
disease is:•A. Acute fatty liver of pregnancy.
•B. Hyperemesis gravidarum.•C. Toxemia of pregnancy.
•D. Intrahepatic cholestsis of pregnancy.•E. HELP syndrome.
![Page 40: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/40.jpg)
BO5:12•12 .The following pregnancy-related liver diseases
coexist together except:•A. Acute fatty liver of pregnancy.
•B. Intrahepatic cholestasis of pregnancy.•C. Toxemia of pregnancy.
•D. HELP syndrome.•E. All of the above.
![Page 41: GIT Cholestatic AI HBD 17](https://reader036.vdocuments.us/reader036/viewer/2022062900/58e8d4251a28abb3398b5ba5/html5/thumbnails/41.jpg)
BO5:13•13 .The following pregnancy-related liver diseases
occur in late pregnancy trimesters except:•A. Acute fatty liver of pregnancy.
•B. Intrahepatic cholestasis of pregnancy.•C. Hyperemesis gravidarum.
•D. HELP syndrome.•E. Eclampsia.